Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Neurokinin 1 receptor antagonists promote chemosensitivity and reverse chemoresistance in colorectal cancer

A receptor antagonist and neurokinin technology, applied in the field of medicine, can solve the problem that the molecular mechanism of NK-1R antagonists has not been well described

Active Publication Date: 2022-05-27
中国人民解放军联勤保障部队第九〇三医院
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the molecular mechanisms underlying the efficacy of NK-1R antagonists in cancer cells are still not well described

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neurokinin 1 receptor antagonists promote chemosensitivity and reverse chemoresistance in colorectal cancer
  • Neurokinin 1 receptor antagonists promote chemosensitivity and reverse chemoresistance in colorectal cancer
  • Neurokinin 1 receptor antagonists promote chemosensitivity and reverse chemoresistance in colorectal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0040] 1 Materials and methods

[0041] 1.1 Data mining in Oncomine. Gene copy number and expression data for patients and cell lines were extracted from the Oncomine database (www.oncomine.org). TACR1 copy number level data were obtained from Reporter 02-072503625 of the Barretina CellLine 2 (GSE36138) dataset. TACR1 mRNA expression levels were obtained from Reporter 208048_at of the GarnettCellLine dataset. TAC1 copy number level data were obtained from Reporter07-097203463 of the Barretina CellLine2 (GSE36138) dataset. TAC1 mRNA expression levels were obtained from Reporter206552_s_at of the GarnettCellLine dataset.

[0042] 1.2 Cell culture. In the research of the present invention, HCT116 and SW620 cells were obtained from the First Affiliated Hospital of Zhejiang University, and HCT116 cells (HCT116 / 5-FU) resistant to 5-FU were obtained from Beijing Beina Chuanglian Biotechnology Research Institute. SW620 was cultured in DMEM (Life Technologies), and HCT116, HCT116 / ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the role of neurokinin 1 receptor antagonists in promoting chemosensitivity and reversing chemoresistance in colorectal cancer. Specifically, the present invention relates to a method of promoting cancer chemotherapy sensitivity in a subject or reversing cancer chemotherapy resistance in a subject, comprising administering a therapeutically effective amount of an NK-1R antagonist to the subject. Furthermore, the present invention relates to a pharmaceutical composition for treating colorectal cancer, which comprises NK‑1R antagonist, chemotherapy drugs, and optional pharmaceutically acceptable carriers.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a method for promoting chemosensitivity and reversing chemoresistance in the treatment of colorectal cancer, and a pharmaceutical product containing a neurokinin 1 receptor antagonist. Background technique [0002] Colorectal cancer (CRC) is the second and third most common cancer diagnosed in women and men, respectively, and mortality is increasing [1] . Since 1995, the incidence, especially among young adults under the age of 50, has increased by 2.2% per year [2] . Using current standard treatments, including surgery, chemotherapy, and radiation, the 5-year relative survival rate for CRC patients is 65%, however, this rate drops to 12% for CRC patients with stage IV disease [3] . Therefore, understanding the pathogenesis of CRC and developing new therapies represent an unmet clinical need for CRC patients. [0003] Substance P (Substance P, SP) is the first member of the tachykini...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K45/06A61P35/00
CPCA61P35/00A61K31/5377A61K31/4545A61K31/555A61K2300/00
Inventor 王喜付彩云邵罡程旭锐王凌菲蒙月明张奇瑜
Owner 中国人民解放军联勤保障部队第九〇三医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com